Subcutaneous Testosterone Cypionate Administration
Subcutaneous testosterone cypionate is an effective and well-tolerated alternative to intramuscular injection, typically dosed at 50-100 mg weekly, though the FDA label currently specifies intramuscular use only. 1
Critical Context: FDA Labeling vs. Clinical Practice
The FDA-approved testosterone cypionate label explicitly states "for intramuscular use only" and recommends 50-400 mg every 2-4 weeks via deep gluteal injection 1. However, substantial clinical evidence demonstrates subcutaneous administration is both effective and preferred by patients.
Dosing Protocol for Subcutaneous Administration
Starting Dose
- Begin with 50 mg weekly subcutaneous injection 2, 3
- This applies across a wide range of body mass indices (19.0-49.9 kg/m²) 2
Dose Adjustment Strategy
- Measure serum testosterone at week 6-7
- Adjust to 50,75, or 100 mg weekly based on trough levels 3
- Target: mid-normal range (450-600 ng/dL) 4, 5
- 92.7% of patients achieve therapeutic range (300-1,100 ng/dL) with dose-adjusted weekly subcutaneous testosterone 3
Injection Technique
- Self-administered subcutaneous injection
- Use 27-gauge, 5/8-inch needle 6
- Over 95% of patients report no injection-related pain 3
Monitoring Schedule
Following Endocrine Society guidelines 4:
Initial Phase (First Year):
- Evaluate at 3-6 months: measure testosterone and hematocrit
- Measure testosterone midway between injections for weekly dosing 4
- If mid-interval testosterone >600 ng/dL or <350 ng/dL, adjust dose or frequency 4
- At 12 months: testosterone and hematocrit
Ongoing Monitoring:
- Annual testosterone and hematocrit measurements
- Annual clinical evaluation for symptom response and adverse effects 4
Prostate Monitoring (if chosen):
- PSA and digital rectal exam at 3-12 months, then annually 4
- Urology referral if PSA increases >1.4 ng/mL above baseline, PSA >4.0 ng/mL, or abnormal digital rectal exam 4
Clinical Advantages of Subcutaneous Route
Research demonstrates clear benefits over intramuscular administration 7, 2:
- Equivalent testosterone exposure (AUC 1.7 vs 1.9 nmol·days/L/mg, p>0.05) 7
- Lower preinjection anxiety
- Reduced pain during and after injection
- Enables self-administration without healthcare provider
- Marked patient preference (20/22 patients preferred subcutaneous over intramuscular) 2
Pharmacokinetic Profile
Weekly subcutaneous dosing produces:
- Steady serum testosterone with minimal peak-trough fluctuation 3, 6
- Mean steady-state concentration of 422-896 ng/dL (dose-dependent) 6
- Dose-proportional exposure 6
- No patient exceeded 1,800 ng/dL at therapeutic doses 3
Safety Considerations
Common Adverse Events (leading to discontinuation in some cases) 3:
- Increased hematocrit (monitor closely; discontinue if >50%)
- Hypertension
- Elevated PSA
Injection Site Reactions:
- Minor and transient in 9/63 patients (14%) 2
- No serious adverse events related to subcutaneous administration 3
Laboratory Monitoring:
- Hemoglobin/hematocrit remains stable (mean 160 vs 153 g/L, p>0.05) 7
- ALT levels unchanged (18 vs 21 IU/L, p>0.05) 7
Critical Pitfall: Timing of Blood Draw
When measuring testosterone on weekly subcutaneous dosing, draw blood midway between injections 4. Without documenting injection timing, testosterone results are uninterpretable 8. This is the most common monitoring error in clinical practice.
Adjustment for Symptom Cycling
If patients report early peak symptoms (acne, mood changes, fluid retention) or late-cycle symptoms (fatigue, reduced libido), consider:
- Increasing injection frequency to twice-weekly or three-times-weekly rather than escalating total weekly dose 8
- This redistributes the same weekly dose for smoother exposure
- Particularly useful in patients with low SHBG or estradiol-related symptoms 8
Contraindications
Per Endocrine Society guidelines 4:
- Prostate cancer
- Breast cancer
- Untreated prolactinoma
- Baseline hematocrit >50%